MiKaela M. Olsen, DNP, APRN-CNS, AOCNS®, FAAN, serves as the Clinical Program Director for Oncology at Johns Hopkins Hospital and the Johns Hopkins Health System. In this role, she partners with oncology nurse leaders, physician leaders, and frontline clinical staff to advance best practices and ensure seamless coordination of care across the health system. She also works closely with oncology service line leadership to align core competencies and harmonize standards of care throughout the Johns Hopkins Cancer service line.

Dr Olsen holds academic appointments as Adjunct Faculty at the Johns Hopkins School of Nursing and Faculty Associate at the University of Maryland School of Nursing.

She co-chairs the Johns Hopkins Health System Venous Access Device Committees and the central line-associated bloodstream infection (CLABSI) Reduction Committee. Additionally, she is the lead editor of the Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice, 2nd Edition (2023) and the Safe Handling of Hazardous Drugs, 4th Edition (2024). Dr Olsen is the co-chair of the American Society of Clinical Oncology/Oncology Nursing Society (ASCO ONS) Antineoplastic Administration Standards (2025). Her scholarship includes numerous publications and presentations on the safe handling of hazardous drugs and the occupational risks faced by health care workers, antineoplastic drug administration and side effect management, central vascular access devices, and prevention of infection.

As an instructor and consultant, Dr Olsen has shared her expertise internationally, traveling to Singapore, the UAE, China, Bulgaria, and Japan to strengthen nursing education in oncology and to raise global awareness of hazardous drug exposure risks and safe handling practices.

Blake Shay, PharmD, MS, is the Pharmacy Manager at St. Joseph’s Women’s and Children’s Hospital in Tampa, Florida. He oversees the Department of Pharmacy for both Women’s and Children’s service lines, including pediatric oncology, infusion services, and the St. Joseph’s Hemophilia Treatment Center. Additionally, Dr Shay co-coordinates the Health-System Pharmacy Administration and Leadership (HSPAL) residency program at BayCare.

As a pharmacy innovator, he co-founded EnOPrep, a sealed system designed for the safe crushing and dissolving of hazardous medications at the point of care for oral and enteral administration. He is an active member of American Society of Health System Pharmacists (ASHP) and Florida Society of Health System Pharmacists (FSHP), has published extensively on hazardous drug safety, and consults as a content expert for gene and cell therapy site readiness.

Appointed by the state of Florida to the Rare Disease Advisory Council, Dr Shay advises the Florida Department of Health on improving health outcomes for individuals with rare diseases. He also serves on the Mercer University College of Pharmacy Alumni Board of Directors. His practice interests include gene and cell therapies, specialty pharmacy, facility design, and hazardous drug safety.